Gt Biopharma Inc

This non-binding "say-on-pay" proposal asks stockholders to approve the company’s executive compensation as disclosed in the proxy statement, giving investors an advisory endorsement opportunity. Management is seeking shareholder approval to signal support for its pay philosophy—designed to attract, retain and motivate executives through salary, cash bonuses and equity awards—and to provide the Board and Compensation Committee with feedback to consider in future pay decisions. The proxy includes detailed disclosure (summary compensation table, option grants, pay-versus-performance reconciliation and narrative) showing increased compensation actually paid to the CEO in 2025 and substantial equity awards; the filing emphasizes the use of equity to align executive and stockholder interests. The Board’s recommendation to vote FOR is grounded in its view that the program supports long-term value creation and is consistent with market practices, while also noting it will consider the advisory vote outcome when setting future compensation. From a governance perspective, the proposal is advisory only and does not change fiduciary duties or prior awards; however, a negative vote could trigger shareholder engagement and possible changes to pay practices. Company-specific context includes a documented increase in compensation in 2025 concurrent with declining cumulative total shareholder return, which may raise investor concern about pay-for-performance alignment. The compensation arrangements include employment agreements with change-in-control and severance provisions and significant option grants; these features may be viewed as retention-focused but may also attract scrutiny if not tied to clear performance metrics. In evaluating the proposal, sophisticated analysts should weigh the Board’s stated rationale for pay design and retention needs against the demonstrated stock performance and the disclosed pay-versus-performance metrics, and consider whether governance safeguards (e.g., Compensation Committee oversight, consultant engagement) sufficiently mitigate agency risk.

This management proposal asks stockholders to authorize a Charter amendment enabling the Company to implement, at the Board’s discretion within one year, a reverse stock split of issued and outstanding common stock at a ratio between 1-for-10 and 1-for-30 and to reduce authorized shares to 25,000,000 common and 1,500,000 preferred. The proximate driver is Nasdaq’s notification of noncompliance with the $1 minimum bid price rule and a subsequent extension of the compliance period; management frames the reverse split as the preferred tool to raise per-share price to regain continued listing. The Board will retain discretion whether and when to effect the split and to select the precise ratio within the authorized range based on market and company-specific factors, which provides flexibility but concentrates timing and ratio power with management. The filing discloses mechanics (no fractional shares issued; exchange agent to sell fractional interests for cash) and accounting/tax consequences (recapitalization treatment), and notes adjustments to equity awards and plan share limits will be made proportionally. The proxy also identifies risks: the split may not provide a durable price increase, could reduce liquidity or market makers, increase odd-lot holdings and transaction costs for small holders, and—combined with a non-proportional reduction in authorized shares—could effectively increase the percentage of authorized-but-unissued shares, raising potential anti-takeover concerns. The Board states it will only effect the split if it believes doing so is in stockholders’ best interests, and that approval merely authorizes but does not compel implementation. For analysts, key evaluation points include assessing (i) the company’s realistic prospects for restoring Nasdaq compliance without a split, (ii) the likelihood that a chosen ratio would sustain a $1+ trading price given the company’s market capitalization and trading history, (iii) possible dilution and issuance strategy using the relatively increased authorized-but-unissued pool, and (iv) governance implications of the Board’s discretionary authority over timing and ratio.

This management proposal requests shareholder approval to add 3,500,000 shares to the 2022 Omnibus Incentive Plan, raising the plan cap to 4,250,000 shares and materially increasing the pool available for future equity awards. Management argues the increase is necessary to continue granting equity awards to attract, retain and motivate executives, directors, employees and consultants and to align their interests with stockholders; the Board projects the additional shares to cover approximately one year of expected grants given current burn rates. The proxy discloses the current plan usage (597,550 options outstanding, 25,935 shares issued, 126,515 available) and quantifies potential overhang and dilution (the proposed increase would represent roughly 8% of outstanding shares under the company’s calculations), enabling investors to assess the magnitude of dilution. The filing also provides historical burn rates and indicates the majority vote required for approval; awards will be at the Compensation Committee’s discretion, which raises governance considerations about allocation and pacing of grants. From a governance and investor perspective, analysts should weigh the retention and incentive benefits of a larger equity pool against dilutionary effects and whether grants will be performance-conditioned or predominantly time-based. The proxy notes that certain insiders could receive future awards, which constitutes a related interest but is routine for equity plans; the Board contends this aligns management incentives with shareholder value creation. Given the company’s small outstanding float and active use of equity for compensation, the proposal’s approval could be material to future share supply and potential equity-financing capacity.

This management proposal would add a multi-year evergreen mechanism to the 2022 Plan, automatically increasing the plan share reserve each year by 2% of outstanding shares for fiscal years 2027 through 2036 unless the Board elects to reduce or omit an increase. Management contends the mechanism provides predictability and reduces the administrative burden and delay of seeking shareholder approval for frequent share increases, enabling more timely compensation planning and hiring. The evergreen increases, while capped by the Board’s discretion, represent a continuing source of dilution whose cumulative effect should be analyzed against historical burn rates and expected future grant levels; the proxy signals intent to manage usage prudently. For governance-minded investors, concerns include the potential for ongoing dilution without annual shareholder review, though mitigants include the Board’s ability to limit or skip increases and Compensation Committee oversight of grant timing and recipients. The filing positions the 2% figure as within market norms and seeks to balance the company’s operational need for awards with stockholders’ interest in limiting dilution; it also discloses potential insider interest since directors and officers may receive awards. Analysts should evaluate this proposal in the context of the company’s capitalization, current plan usage, pipeline and hiring needs, and whether grant practices will include performance-based vesting to align awards with long-term shareholder value. The Board recommends FOR, arguing that the evergreen provision supports retention and alignment while preserving oversight.